Fengting Yan, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Pfizer
    Topic:
    The Best of Hematology and Breast Cancer 2025
    Date added:
    10/08/2021
    Date updated:
    10/02/2024
    Relationship end date:
    12/31/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Astrazeneca
    Topic:
    The Best of Hematology and Breast Cancer 2025
    Date added:
    10/02/2024
    Date updated:
    10/02/2024
    Relationship end date:
    12/31/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Gilead
    Topic:
    The Best of Hematology and Breast Cancer 2025
    Date added:
    10/02/2024
    Date updated:
    10/02/2024
    Relationship end date:
    12/31/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Eli Lilly
    Topic:
    The Best of Hematology and Breast Cancer 2025
    Date added:
    10/02/2024
    Date updated:
    10/02/2024
    Relationship end date:
    12/31/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Merck
    Topic:
    The Best of Hematology and Breast Cancer 2025
    Date added:
    10/02/2024
    Date updated:
    10/02/2024
    Relationship end date:
    12/31/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Daiichi
    Topic:
    The Best of Hematology and Breast Cancer 2025
    Date added:
    10/02/2024
    Date updated:
    10/02/2024
    Relationship end date:
    12/31/2025
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Genentech
    Topic:
    The Best of Hematology and Breast Cancer 2025
    Date added:
    10/02/2024
    Date updated:
    10/02/2024
    Relationship end date:
    12/31/2025
Return to Summit on Cancer Health Disparities (SCHD25)